

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/319700169>

Chylous Ascites in HIV/TB Co-Infections: Case Report, Challenges of Management in a Resource-Poor Setting and Literature Review

Article · September 2017

DOI: 10.118535/jmscr/v5i9.67

CITATIONS

0

READS

38

1 author:



[Olusegun Adesola Busari](#)

Afe Babalola University, Ado Ekiti/Federal Teaching Hospital, Ido Ekiti, Nigeria

80 PUBLICATIONS 648 CITATIONS

[SEE PROFILE](#)



Chylous Ascites in HIV/TB Co-Infections: Case Report, Challenges of Management in a Resource-Poor Setting and Literature Review

Authors

**Olusegun Adesola Busari¹, Oluwaserimi Adewumi Ajetunmobi²
Idowu Oluseyi Adebara³, Olusegun Emmanuel Gabriel², Olumide Adewara³
Olayide Elegbede², Olusogo Ebenezer Busari⁴**

¹Department of Internal Medicine, Federal Teaching Hospital, Ido-Ekiti, Nigeria

²Department of Family Medicine, Federal Teaching Hospital, Ido-Ekiti, Nigeria

³Department of Obstetrics and Gynaecology, Federal Teaching Hospital, Ido-Ekiti, Nigeria

⁴Department of Haematology, Afe Babalola University, Ado-Ekiti, Nigeria

Corresponding Author

Olusegun Adesola Busari

Department of Internal Medicine, Federal Teaching Hospital, Ido-Ekiti, Nigeria

Email: olubusari@yahoo.com, +234(0)8035761603

Abstract

Chylous ascites is an uncommon clinical condition characterized by extravasation of milky chyle into the peritoneal cavity usually as a result of either blockage of the lymphatics or leakage from inadvertent trauma during surgeries. This is a report of a case of chylous ascites in a 32-year old Nigerian with HIV/TB co-infections. The report also highlights the challenges associated with management of chylous ascites in a resource-poor setting. The patient was managed conservatively with diuretic therapy, salt and fluid restrictions and elevation of the lower limbs. Although, the ascites re-accumulated initially, it finally resolved and she was followed up for at least six months with no recurrence.

Keywords: *Chylous ascites, HIV/TB co-infections, resource-poor settings, management challenges.*

Introduction

Human immunodeficiency virus (HIV) increases the risk of infection with Mycobacterium tuberculosis (MTB).^[1] Extrapulmonary and disseminated tuberculosis (TB) such is common in HIV disease.^[2] Chylous ascites (CA) is an uncommon clinical condition.^[3] It is the extravasation of milky chyle into the peritoneal cavity. It usually results either due to blockage of the lymphatics or leak due to inadvertent trauma during surgeries.^[4] These conditions

particularly include neoplasms such as lymphomas and disseminated carcinomas and abdominopelvic surgeries.^[5] However, it may also be due to an infective cause and few cases have been reported in association with HIV.^[6,7] We report a case of CA in a 32-year old African with HIV and disseminated TB. We also highlight the challenges associated with management of CA in a resource-poor setting where we work and lastly write a literature review on it.

Case Report

A 32-year old woman presented with cough and progressive abdominal swelling for three months. There was leg swelling which was disproportionate with increase in abdominal girth but no facial swelling. She denied having fever, chest pain, dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, dysuria, nocturia or haematuria. No previous history of TB, jaundice or blood transfusion. No alcohol ingestion, cigarette smoking or use of illicit substances.

On physical examination, she was pale, anicteric, acyanosed, afebrile with minimal bilateral pitting pedal oedema. There was no palpably enlarged peripheral lymph node. She had oral thrush. Her body weight was 47kg. Respiratory system examination disclosed dull percussion notes and inspiratory crackles in the right lower lung zone. The abdominal examination revealed a non-tender doughy abdomen with marked ascites demonstrable by shifting dullness. The liver and spleen were not enlarged and kidneys not ballotable. Bowel sounds were nomaactive. Other systems were normal.

The patient had provider-initiated HIV counseling and testing and found to be positive for HIV 1. She had a CD4⁺ T cell count of 45 cells/ μ l. Haemoglobin concentration was 9.2g/dl and total white blood cells count $1.7 \times 10^9/l$. Although the result of sputum examination was negative for MTB, the chest X-ray showed patchy reticulo-nodular opacities in the left lobe and a minimal left sided pleural effusion. The erythrocyte sedimentation rate was also elevated; 60mm/hr. Diagnostic paracentesis was done and sent for biochemical analysis and cytology. The results are as follow: total protein 13.4g/l, albumin 5.0g/l, glucose 4.9mmol/l and triglycerides 1.5mmol/l. Ascitic fluid was negative for Gram staining and culture yielded no growth for bacteria and MBT. Leucocytes were scanty, 100 cells/mm³, and no malignant cells. Abdominopelvic ultrasonography revealed gross ascites and few mesenteric and para-aortic lymph nodes. Liver, gall bladder, bile duct system, spleen, pancreas and kidneys were

sonologically normal. Serum liver function test was normal except for albumin which was low. She was non-reactive for hepatitis B surface antigen and anti HCV antibodies. Abdominal CT scan was not done because of financial constraints and lymphangiogram was not available anywhere in Nigeria and West African subregion.

The diagnosis was disseminated TB (pulmonary and abdominal components) and she was started on antituberculosis drugs, isoniazid, rifampicin, ethambutol and pyrazinamide. Two weeks after, the patients was also commenced on antiretroviral drugs, zidovudine, lamivudine and efavirenze. The chylous ascites was managed conservatively only with diuretic therapy, salt and fluid restriction and elevation of the lower limbs. Parenteral nutrition and medium sized triglycerides were not available. However, the ascites gradually resolved and she was discharged after about eight weeks on admission. Sadly the ascites started reaccumulating about two months after discharge despite good adherence to antituberculosis and antiretroviral drugs and cotrimoxazole prophylaxis. She was readmitted and managed again conservatively only with diuretic therapy, salt and fluid restriction and elevation of the lower limbs. Thereafter, she has been followed up for at least six months with no recurrence of the CA.

Discussion

Although CA is a rare condition, it has been reported before in association with complications of HIV and TB. ^[6,7] Thus one major highlight of this work is about the challenges of management of chylous ascites in our institution which is in a resource-poor setting in sub-Sahara Africa. Besides antituberculous and antiretroviral drugs, furosemide and spironolactone were the only other drugs we used. Parenteral nutrition and medium sized triglycerides are not available in our setting and neither the newer drugs particularly octreotide. Infrastructure and capacity for surgical intervention in case of failure of conservative

measures or rapid accumulation of ascites are also not available.

Chylous ascites occurs majorly from two mechanisms: a disruption of the abdominal lymphatics which may be due to neoplasm, inflammation or trauma particularly during surgery^[3-5] and an increase in the abdominal lymph production with ineffective development of collateral flow. The initial mechanism is more likely in infectious diseases.^[6,7] Increase in the abdominal lymph production due to high venous pressure is probably responsible for few cases of CA associated with constrictive pericarditis^[7-10] and severe heart failure.^[11,12]

Abdominal swelling is the most common symptom in CA. However, the features of the primary disease may dominate the clinical picture. Our patient had both abdominal and pedal swelling. Sepsis is the most common complication and sudden deaths have been reported. The case reported by Talluri *et al*^[4] was complicated by sepsis although she recovered and was discharged. In this case report there was no sepsis. Prognosis in CA depends on the primary disease. Generally the prognosis in nonsurgical ascites is poorer.

Chylous ascites is diagnosed when the ascites triglyceride level is more than 1.24mmol/l or 110mg/dl. Other common laboratory features of CA are shown in Table 1. The objectives of the treatment of CA are to relieve the symptoms associated with abdominal distention, reduce the flow of lymph into the mesenteric lymph nodes and replace the nutritional losses.^[5] These objectives can be achieved by use of diuretics with salt and fluid restrictions, dietary measures, therapeutic paracentesis and other things such as elevation of lower limbs and use of supportive stockings.^[14] The use of newer drugs such as somatostatin analog and etilefrine has also been described.^[15,16] Also, orlistat, the saturated derivative of lipstatin, a potential natural inhibitor of pancreatic lipases, has been reportedly used in a patient with poor adherence with a low fat diet.^[17] Dietary measures form the cornerstone of conservative management of CA. These include

high protein, low fat and medium chain TG diet. Low and medium chain TG diet bypasses the lymphatics and reduces the flow of chyle into them by diffusing directly into the portal venous system unlike the long chain TG which passes through the lymphatics.^[5] Bowel rest and total parenteral nutrition may be beneficial particularly in patients who cannot tolerate orally and are also malnourished.^[5]

Therapeutic paracentesis is a palliative measure which often provides immediate symptomatic relief. The drawbacks are that it is ineffective alone and often reaccumulate necessitating repeated paracentesis.

Somatostatin analogues, octreotide and lanreotide, have been used in the management of CA.^[5,15,16,18] Somatostatin significantly attenuates postprandial increase in TG level by reducing gastric emptying and decreasing intestinal absorption of fat, and more importantly by inhibiting lymphatic flow in the major lymph vessels.

Surgical intervention when there is failure of optimal conservative management. This may be by direct ligation of the leaking lymphatics with or without use of fibrin glue and absorbable mesh or by establishing a peritoneovenous shunt.^[19,20] Peritoneovenous shunting is only used in a small group of patients with rapid accumulation of CA. This avoids nutritional depletion associated with repeated paracentesis as the fluid is recirculated. However, shunt failure is common and complications such as sepsis may occur.^[14] *Transjugular intrahepatic portosystemic shunt* has been used successfully in CA due to liver cirrhosis.^[21]

Conclusion

Although CA is a rare condition, this is a case report in HIV/TB co-infections. In resource-constraint settings, particularly in sub Saharan Africa where there is extreme poverty and dilapidated healthcare infrastructure, there are challenges in the effective management of diseases and in this case CA.

Reference

1. Chaisson RE, Marinson NA. Tuberculosis in Africa-combating an HIV-driven crisis. *N Eng J Med* 2008; 358: 1089-1092
2. Leeds IL, Magee MJ, Kurbatova EV, et al. Site of Extrapulmonary Tuberculosis is Associated with HIV Infection. *Clin Infect Dis* 2012; 55:75
3. von Reyn CF, Kimambo S, Mtei L, Arbeit RD, Maro I, Bakari M, Matee M, Lahey T. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. *Int J Tuberc Lung Dis* 2011; 15:1087-1092
4. Talluri SK, Nuthakki H, Tadakamalla A, Talluri J, Besur S. Chylous ascites. *North Am J Med Sci* 2011; 3(9): 438-440
5. Shan SS, Ahmed K, Smith R, Mallina R, Akhbari P, Khan MS. Chylous ascites in a TB/HIV co-infected patient: case report and literature review. *Journal of Medical Case Report* 2008; 2: 3 doi: 10.1186/1752-1947-2-3. Available at <http://www.jmedicalcasereports.com/contents/2/1/3>
6. Lin J, Lai C, Chen Y, Chang L, Lee SS, Lin H. Immune reconstitution inflammatory syndrome presenting as chylothorax in a patient with HIV and Mycobacterium tuberculosis coinfection. *BMC Infectious Diseases* 2010, 10: 321. Available at <http://www.biomedcentral.com/1471-2334/10/321>
7. Summachiwakij S, Tungsubutra W, Koomanachai P, Charoenratanakul S. Chylous ascites and chylothorax due to constrictive pericarditis in a patient infected with HIV: a case report. *Journal of Medical Case Reports* 2012, 6: 163. Available at <http://www.jmedicalcasereports.com/contents/6/1/163>
8. Savage MP, Muñoz SJ, Herman WM, Kusiak VM: Chylous ascites caused by constrictive pericarditis. *Am J Gastroenterol* 1987, 82:1088-1090
9. Guneri S, Nazli C, Kinay O, Kirimli O, Mermut C, Hazan E: Chylous ascites due to constrictive pericarditis. *Int J Card Imaging* 2000, 16:49-54
10. Guneri S, Nazli C, Kinay O, Kirimli O, Mermut C, Hazan E. Chylous ascites due to constrictive pericarditis. *Int Card Imaging* 2000, 16: 49-54
11. Williams AT, Schneider RP: Chylous ascites should suggest constrictive pericarditis even in a patient with cirrhosis. *J ClinGastroenterol* 1990, 12:581-584
12. Villena V, de Pablo A, Martin-Escribano P: Chylothorax and chylous ascites due to heart failure. *EurRespir J* 1995, 8:1235-1236
13. Hurley MK, Emiliani VJ, Comer GM, Patel A, Navarro C, Maiki CO: Dilated cardiomyopathy associated with chylous ascites. *Am J Gastroenterol* 1989, 84:1567-1569
14. Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. *Ann Intern Med* 1982; 96(3): 358-364
15. Llan I, Yoram M, Jacob G, Jacob R. The diagnosis and management of postoperative chylous ascites: review article. *J Urol* 2002; 167: 449-457
16. Ijichi H, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, et al. Successful management of chylous ascites after living donor liver transplantation with somatostatin. *Liver Int* 2008; 28 (1): 143-145
17. Baran M, Cakir M, Yuksekkaya HA, Arikan C, Aydin U, Aydogdu S, et al. Chylous ascites after living related liver transplantation treated with somatostatin analogue and parenteral nutrition. *Transplant Proc* 2008; 40(1): 320-321

18. Chen J, Lin RK, Hassanein T. Use of orlistat (xenical) to treat chylous ascites. *J ClinGastroenterol* 2005; 39(9): 831-833
19. Berzigotti A, Magalotti D, Cocci C, Angeloni L, Pironi L, Zoli M. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report. *Dig Liver Dis* 2006; 38(2): 138-142
20. Zeidan S, Delarue A, Rome A, Roquelaure B. Fibrin glue application in the management of refractory chylous ascites in children. *J Paediatr Gastroenterol Nutr* Apr 2008; 46(4): 478-481
21. Matsufuji H, Nishio T, Hosoya R. Successful treatment for intractable chylous ascites in a child using a peritoneovenous shunt. *PaediatrSurgInt* 2006; 22(5): 471-473
22. De Vries GJ, Ryan BM, de Bievre M et al. Cirrhosis related ascites successfully treated with TIPS. *Euro J Gastroenterol Hepatol* 2005;17(4): 463-466.